Midatech Pharma Stock Price, News & Analysis (LON:MTPH)

GBX 44.50 -1.00 (-2.20 %)
(As of 01/17/2018 03:17 PM ET)
Previous CloseGBX 44.50
Today's RangeGBX 43 - GBX 45.50
52-Week RangeGBX 34 - GBX 148
Volume15,454 shs
Average Volume38,532 shs
Market Capitalization£27.34 million
P/E Ratio-90.82
Dividend YieldN/A
BetaN/A

About Midatech Pharma (LON:MTPH)

Midatech Pharma logoMidatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company's segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms. The Commercial segment distributes and sells the commercial products. Its products include Zuplenz, Gelclair, Oravig and Soltamox. Zuplenz is an oral soluble film indicated for moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Gelclair is a product indicated for the management and relief of pain due to oral mucositis. Oravig is an orally dissolving buccal tablet approved for oral thrush. Soltamox is an oral liquid solution of tamoxifen citrate for the prevention of breast cancer.

Receive MTPH News and Ratings via Email

Sign-up to receive the latest news and ratings for MTPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorBio Therapeutic Drugs
SymbolLON:MTPH
CUSIPN/A
Phone+44-1235-841575

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-90.8163265306122
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX (0.49)
Net IncomeN/A
Net Margins-262.24%
Return on Equity-43.66%
Return on Assets-35.34%

Miscellaneous

EmployeesN/A
Outstanding Shares61,030,000

Midatech Pharma (LON:MTPH) Frequently Asked Questions

What is Midatech Pharma's stock symbol?

Midatech Pharma trades on the London Stock Exchange (LON) under the ticker symbol "MTPH."

How were Midatech Pharma's earnings last quarter?

Midatech Pharma PLC (LON:MTPH) announced its quarterly earnings data on Thursday, September, 28th. The company reported ($19.00) earnings per share for the quarter. The firm earned $3.02 million during the quarter. Midatech Pharma had a negative net margin of 262.24% and a negative return on equity of 43.66%. View Midatech Pharma's Earnings History.

Where is Midatech Pharma's stock going? Where will Midatech Pharma's stock price be in 2018?

2 equities research analysts have issued 12-month price objectives for Midatech Pharma's stock. Their predictions range from GBX 96 to GBX 297. On average, they expect Midatech Pharma's stock price to reach GBX 196.50 in the next twelve months. View Analyst Ratings for Midatech Pharma.

Who are some of Midatech Pharma's key competitors?

Who are Midatech Pharma's key executives?

Midatech Pharma's management team includes the folowing people:

  • James Neil Phillips, Chief Executive Officer, Director
  • Nicholas John Robbins-Cherry, Finance Director, Director (Age 45)
  • Craig Cook, Chief Operating Officer / Chief Medical Officer
  • Daniel David Palmer Ph.D., Chief Scientific Officer
  • Justin Barry, Head - Manufacturing
  • Tim Sparey, Chief Business Officer
  • Rolf Stahel, Non-Executive Chairman of the Board (Age 72)
  • Simon De Vries, Non-Executive Director (Age 56)
  • John Joseph Johnston, Non-Executive Director
  • Michele Luzi, Non-Executive Director (Age 57)

How do I buy Midatech Pharma stock?

Shares of Midatech Pharma and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Midatech Pharma's stock price today?

One share of Midatech Pharma stock can currently be purchased for approximately GBX 44.50.

How big of a company is Midatech Pharma?

Midatech Pharma has a market capitalization of £27.34 million.

How can I contact Midatech Pharma?

Midatech Pharma's mailing address is 65 Innovation Drive, Milton Park, ABINGDON, OX14 4RQ, United Kingdom. The company can be reached via phone at +44-1235-841575.


MarketBeat Community Rating for Midatech Pharma (MTPH)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  158 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  208
MarketBeat's community ratings are surveys of what our community members think about Midatech Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Midatech Pharma (LON:MTPH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 196.50GBX 196.50GBX 196.50GBX 218.50

Midatech Pharma (LON:MTPH) Consensus Price Target History

Price Target History for Midatech Pharma (LON:MTPH)

Midatech Pharma (LON:MTPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
10/13/2017N+1 SingerLower Price TargetBuyGBX 140 -> GBX 96View Rating Details
5/22/2017Panmure GordonReiterated RatingBuyGBX 297View Rating Details
(Data available from 1/17/2016 forward)

Earnings

Midatech Pharma (LON:MTPH) Earnings History and Estimates Chart

Earnings by Quarter for Midatech Pharma (LON:MTPH)

Midatech Pharma (LON MTPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/28/2017S1 2017GBX (19)GBX 302 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Midatech Pharma (LON:MTPH) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Midatech Pharma (LON:MTPH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Midatech Pharma (LON MTPH) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Midatech Pharma (LON:MTPH)

Midatech Pharma (LON MTPH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2015Phillips,James NeilInsiderBuy960GBX 204£1,958.40
6/26/2015Phillips,James NeilInsiderBuy2,572GBX 3.09GBX 7,947.48
6/24/2015Phillips,James NeilInsiderBuy2,000GBX 2.87GBX 5,740
6/23/2015Robbins-Cherry,NicholasInsiderBuy500GBX 2.88GBX 1,440
(Data available from 1/1/2013 forward)

Headlines

Midatech Pharma (LON MTPH) News Headlines

Source:
DateHeadline
Midatech and UCSF receive IND approval for DIPG treatment MTX110 - GlobeNewswire (press release)Midatech and UCSF receive IND approval for DIPG treatment MTX110 - GlobeNewswire (press release)
globenewswire.com - January 17 at 9:08 AM
Midatech and UCSF receive IND approval for DIPG treatment MTX110Midatech and UCSF receive IND approval for DIPG treatment MTX110
finance.yahoo.com - January 16 at 9:25 AM
Midatech receives confirmation that its Q-Octreotide (MTD201) first in-human EU study is approvedMidatech receives confirmation that its Q-Octreotide (MTD201) first in-human EU study is approved
finance.yahoo.com - January 9 at 9:23 AM
Midatech Loan Agreement with MidCap FinancialMidatech Loan Agreement with MidCap Financial
finance.yahoo.com - January 2 at 9:19 AM
Midatech Pharma US initiates Gelclair® Phase IV trial to study oral mucositis in stem cell transplant patientsMidatech Pharma US initiates Gelclair® Phase IV trial to study oral mucositis in stem cell transplant patients
finance.yahoo.com - December 20 at 9:23 AM
Is Midatech Pharma Plc (AIM:MTPH) Undervalued?Is Midatech Pharma Plc (AIM:MTPH) Undervalued?
finance.yahoo.com - October 28 at 8:28 AM
Midatech Pharma Plc :MTPH-GB: Earnings Analysis: For the six months ended June 30, 2017 : October 23, 2017Midatech Pharma Plc :MTPH-GB: Earnings Analysis: For the six months ended June 30, 2017 : October 23, 2017
finance.yahoo.com - October 24 at 7:20 AM
N+1 Singer Trims Midatech Pharma PLC (MTPH) Target Price to GBX 96N+1 Singer Trims Midatech Pharma PLC (MTPH) Target Price to GBX 96
www.americanbankingnews.com - October 13 at 2:32 PM
Midatech Pharma PLC - StreetInsider.comMidatech Pharma PLC - StreetInsider.com
www.streetinsider.com - September 29 at 1:21 PM
Midatech Pharma PLC (MTPH) Releases Quarterly  Earnings ResultsMidatech Pharma PLC (MTPH) Releases Quarterly Earnings Results
www.americanbankingnews.com - September 28 at 8:24 AM
Midatech Pharma Plc: Midatech submits MTD201 CTA filing for first in human study in carcinoid cancer and acromegaly - NasdaqMidatech Pharma Plc: Midatech submits MTD201 CTA filing for first in human study in carcinoid cancer and acromegaly - Nasdaq
www.nasdaq.com - September 4 at 7:42 PM
Midatech Pharma Plc: Completion of pre-clinical liver cancer programmeMidatech Pharma Plc: Completion of pre-clinical liver cancer programme
finance.yahoo.com - July 27 at 4:32 AM
Midatech Pharma Plc: Trading Update and Notice of ResultsMidatech Pharma Plc: Trading Update and Notice of Results
finance.yahoo.com - July 18 at 11:59 PM
[$$] Biotech and pharma companies hope for better in 2017[$$] Biotech and pharma companies hope for better in 2017
www.ft.com - January 6 at 7:24 PM
Form 6-K Midatech Pharma Plc For: Nov 22Form 6-K Midatech Pharma Plc For: Nov 22
www.streetinsider.com - November 22 at 10:29 AM
Midatech Pharma Plc: Commencement of First in Human Immunotherapy Study Using Gold Nanoparticle TechnologyMidatech Pharma Plc: Commencement of First in Human Immunotherapy Study Using Gold Nanoparticle Technology
www.nasdaq.com - October 1 at 5:36 PM
Half Year 2016 Midatech Pharma PLC Earnings Release - Time Not SuppliedHalf Year 2016 Midatech Pharma PLC Earnings Release - Time Not Supplied
biz.yahoo.com - September 2 at 11:06 AM
Is this stock the best buy in its sector following today’s update?Is this stock the best buy in its sector following today’s update?
uk.finance.yahoo.com - August 10 at 9:24 AM
Midatech Pharma Plc: Grant funding received to explore Midatechs gold nanoparticle technology in immunotherapyMidatech Pharma Plc: Grant funding received to explore Midatech's gold nanoparticle technology in immunotherapy
www.msn.com - July 7 at 6:20 PM

SEC Filings

Midatech Pharma (LON:MTPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Midatech Pharma (LON MTPH) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.